Publications by authors named "J Nagarajah"
Purpose: This study aimed to determine the effect of model selection on simplified dosimetry for the kidneys using Bayesian fitting (BF) and single-time-point (STP) imaging.
Methods: Kidney biokinetics data of [Lu]Lu-PSMA-617 from mHSPC were collected using SPECT/CT after injection of (3.1 ± 0.
Article Synopsis
- This study examined bleeding outcomes after thrombolytic therapy in STEMI patients at a Malaysian hospital from 2016 to 2020.
- Out of 941 patients, 16.6% experienced bleeding, with major and minor bleeding linked to higher in-hospital mortality rates.
- Age and Malaysian Chinese ethnicity were associated with higher bleeding risk, while being a foreigner and smoking were linked to lower risk; gastrointestinal bleeding was notably more common in patients treated with streptokinase.
Aim: The objective of this study was to compare the detection rates of [F]PSMA-1007 and [F]Fluciclovine in early biochemical recurrence (BCR) of prostate cancer, i.e. with low prostate-specific antigen (PSA) levels (0.
View Article and Find Full Text PDFArticle Synopsis
- There is a critical need for new treatments for recurrent salivary gland cancers, with current options being limited.
- A pilot study tested the safety and effectiveness of [Lu]Lu-PSMA-I&T therapy on patients with adenoid cystic carcinoma (AdCC) and salivary duct carcinoma (SDC), aiming to include 10 AdCC and 5 SDC patients.
- Results showed that 67% of AdCC patients were eligible, but there were no objective responses; however, some exhibited stable disease for over 6 months, and the study faced challenges with high screen failure rates in SDC patients.
Article Synopsis
- This study investigates the effectiveness and safety of a combination therapy using immune checkpoint inhibitors (ICIs) for certain subgroups of metastatic castration-resistant prostate cancer (mCRPC) patients who show an immunogenic profile.
- The trial involved 69 patients with specific genetic markers and assessed the disease control rate after treatment, aiming to exceed 22%.
- Results showed that 38% of patients achieved disease control beyond 6 months, with the highest success in patients with mismatch repair deficiency, but treatment led to significant side effects in some cases, with 20% permanently discontinuing therapy.